FDA Import Refusal 799-4132769-2/11/7 — Boehringer Ingelheim Canada
The FDA refused shipment 799-4132769-2/11/7 from Boehringer Ingelheim Canada (Canada) on Nov 8, 2019. The refused product falls under Drugs and Biologics — DAPAGLIFLOZIN (ANTI-DIABETIC). Cited charge: 75 This firm has 5 or more other import refusals on record.
Refusal details
- Date
- Nov 8, 2019
- Country
- Canada
- Product Category
- Drugs and Biologics
- Product Code
- 61PDB70 DAPAGLIFLOZIN (ANTI-DIABETIC)
- Charges
- 75